ADA Says All Diabetes Patients Should Be Screened for Nonalcoholic ... - STAT
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
PubMed • GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
As devastating as it is, cirrhosis is not the only end point I’m worried about here. I care about NAFLD and NASH—and you should too—because they represent the tip of the iceberg of a global epidemic of metabolic disorders, ranging from insulin resistance to type 2 diabetes. Type 2 diabetes is technically a distinct disease, defined very clearly by
... See morePeter Attia MD • Outlive: The Science and Art of Longevity
Are you treating the symptom or the disease?
